How many insider trades does FilingIQ track for LGND?

FilingIQ tracks 946 Form 4 insider transactions for LGND (LIGAND PHARMACEUTICALS INC), covering filings from Feb 23, 2008 onwards. 92 of those were filed in the last 90 days.

Are LGND insiders net buyers or net sellers?

Across the full Form 4 history for LGND, 28 transactions (3%) were open-market purchases and 264 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LGND insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is LGND in?

LIGAND PHARMACEUTICALS INC (LGND) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.69B.

LGND insider trading

NasdaqGM Healthcare

LIGAND PHARMACEUTICALS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

946

Last 90 days

Buys / sells

3% / 28%

Market cap

$3.69B

About LIGAND PHARMACEUTICALS INC

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Company website: www.ligand.com

LGND insider activity at a glance

FilingIQ has scored 946 insider transactions for LGND since Feb 23, 2008. The most recent filing in our index is dated May 13, 2026.

Across the full history, 28 open-market purchases and 264 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LGND insider trades is 61.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LGND trades on FilingIQ Raw filings on SEC EDGAR

Latest LGND Form 4 filings

Espinoza Octavio Chief Financial Officer

S Mar 4, 2025

Espinoza Octavio Chief Financial Officer

S Dec 23, 2024

Espinoza Octavio Chief Financial Officer

S May 17, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading LGND

Espinoza Octavio

40 trades · score 69.0

Frequently asked

How many insider trades does FilingIQ track for LGND?: FilingIQ tracks 946 Form 4 insider transactions for LGND (LIGAND PHARMACEUTICALS INC), covering filings from Feb 23, 2008 onwards. 92 of those were filed in the last 90 days.
Are LGND insiders net buyers or net sellers?: Across the full Form 4 history for LGND, 28 transactions (3%) were open-market purchases and 264 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LGND insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is LGND in?: LIGAND PHARMACEUTICALS INC (LGND) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $3.69B.

Methodology & sources

Every LGND insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.